论文部分内容阅读
缺血再灌注损伤在临床中十分常见而且难以避免,可导致较高的病残率。从其发病机制的不同环节进行治疗是减轻缺血再灌注损伤较为理想的方法。细胞内游离钙被认为在缺血再灌注后导致细胞死亡的级联反应中发挥主要作用。近年来对细胞内钙通道Ryanodine受体阻滞剂丹曲林的研究进展迅速,其药理作用机制主要是抑制细胞内质网和肌浆网的钙释放。本文对缺血再灌注损伤及Ryanodine受体等细胞内钙通道予以综述。
Ischemia-reperfusion injury is clinically very common and difficult to avoid, leading to a higher morbidity. From different aspects of its pathogenesis of treatment is to reduce ischemia-reperfusion injury is the ideal method. Intracellular free calcium is thought to play a major role in the cascade of cell death that occurs after ischemia-reperfusion. In recent years, rapid progress has been made on the study of Dantrulin, a blocker of Ryanodine receptor in intracellular calcium channels. Its pharmacological mechanism is mainly to inhibit calcium release from the endoplasmic reticulum and sarcoplasmic reticulum. This article reviews the intracellular calcium channels such as ischemia-reperfusion injury and Ryanodine receptors.